1 day Ago By Defense World Staff
Co-Diagnostics, Inc. ( NASDAQ:CODX – Get Free Report ) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 326,900 shares, an increase of 8.
6% from the August 15th total of 300,900 shares. Based on an average daily trading volume, of 278,500 shares, the short-interest ratio is currently 1.2 days.
Analyst Upgrades and Downgrades Separately, HC Wainwright lowered their target price on Co-Diagnostics from $2.00 to $1.50 and set a “neutral” rating for the company in a report on Monday, August 12th.
Read Our Latest Stock Analysis on Co-Diagnostics Co-Diagnostics Stock Performance Co-Diagnostics ( NASDAQ:CODX – Get Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.
34) by $0.09. Co-Diagnostics had a negative return on equity of 44.
69% and a negative net margin of 411.18%. The firm had revenue of $2.
66 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts predict that Co-Diagnostics will post -1.
23 EPS for the current year. Institutional Trading of Co-Diagnostics A hedge fund recently bought a new stake in Co-Diagnostics stock. Koss Olinger Consulting LLC acquired a new stake in shares of Co-Diagnostics, Inc.
( NASDAQ:CODX – Free Report ) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned about 0.
19% of Co-Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 14.99% of the company’s stock.
About Co-Diagnostics ( Get Free Report ) Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. Featured Articles Five stocks we like better than Co-Diagnostics What is the Dogs of the Dow Strategy? Overview and Examples How Much Can You Make in Stocks in One Month? Canada Bond Market Holiday: How to Invest and Trade This Is the Top Large-Cap Stock Insiders Are Buying Manufacturing Stocks Investing Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.
com's FREE daily email newsletter ..
